By Associate Professor Deborah Cromer

Preprints

Berry MT; MacIntyre CR; Cromer D; Hacker A; Davenport MP; Khoury DS, 2024, Optimal deployment of limited vaccine supplies to combat mpox, http://dx.doi.org/10.1101/2024.11.03.24316551

Hao T; Ryan GE; Lydeamore MJ; Cromer D; Wood J; McVernon J; McCaw JM; Shearer FM; Golding N, 2024, Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19, http://dx.doi.org/10.1101/2024.10.17.24314397

Conway E; Walker C; Lydeamore M; Golding N; Ryan G; Mavec D; Oates J; Kabashima G; Price DJ; Shearer F; Cromer D; Davenport MP; McCaw J; Eriksson EM; Hodgkin PD; Wu L; Le TP; Baker CM; Mueller I; McVernon J, 2024, Optimal timing of booster doses in a highly vaccinated population with minimal natural exposure to COVID-19, http://dx.doi.org/10.1101/2024.05.14.24307386

Cromer D; Reynaldi A; Hie A; Schlub T; Juno J; Wheatley A; Kent S; Khoury D; Davenport M, 2024, Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates, http://dx.doi.org/10.1101/2024.02.08.24302032

Le T; Conway E; Akpan E; Abell I; Abraham P; Baker C; Campbell P; Cromer D; Lydeamore M; McDonough Y; Mueller I; Ryan G; Walker C; Wang Y; Carvalho N; McVernon J, 2023, Cost-effective boosting allocations in the post-Omicron era of COVID-19 management, http://dx.doi.org/10.1101/2023.11.14.23298536

Lee WS; Tan H-X; Reynaldi A; Esterbauer R; Koutsakos M; Nguyen J; Amarasena T; Kent H; Aggarwal A; Turville S; Taiaroa G; Kinsella P; Liew KC; Tran T; Williamson D; Cromer D; Davenport M; Kent S; Juno J; Khoury D; Wheatley A, 2023, Durable reprogramming of neutralising antibody responses following breakthrough Omicron infection, http://dx.doi.org/10.1101/2023.02.19.23286159

Selva KJ; Ramanathan P; Haycroft ER; Reynaldi A; Cromer D; Tan CW; Wang L-F; Wines B; Hogarth M; Downie L; Davis S; Purcell RA; Kent H; Juno J; Wheatley A; Davenport M; Kent SJ; Chung A, 2023, Lasting first impression: Pre-existing immunity restricts mucosal antibody responses during Omicron breakthrough, http://dx.doi.org/10.1101/2023.03.28.23287848

Elias K; Khan S; Stadler E; Schlub T; Cromer D; Polizzotto M; Kent S; Turner T; Davenport M; Khoury D, 2023, Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: A systematic review and meta-analysis, http://dx.doi.org/10.1101/2023.06.18.23291566

Stadler E; Cromer D; Ogunlade S; Ongoiba A; Doumbo S; Kayentao K; Traore B; Crompton P; Portugal S; Davenport M; Khoury D, 2022, A role for super-spreaders in carrying malaria parasites across the months-long dry season, http://dx.doi.org/10.1101/2022.04.28.22274398

Khoury D; Schlub T; Cromer D; Steain M; Fong Y; Gilbert P; Subbarao K; Triccas J; Kent S; Davenport M, 2022, Correlates of protection, thresholds of protection, and immunobridging in SARS-CoV-2 infection, http://dx.doi.org/10.1101/2022.06.05.22275943

Stadler E; Chai KL; Schlub T; Cromer D; Polizzotto M; Kent S; Beecher C; White H; White H; Turner T; Skoetz N; Skoetz N; Estcourt L; McQuilten Z; Wood E; Khoury D; Davenport M, 2022, Determinants of passive antibody efficacy in SARS-CoV-2 infection, http://dx.doi.org/10.1101/2022.03.21.22272672

Stadler E; Burgess M; Schlub T; Chai KL; McQuilten Z; Wood E; Polizzotto M; Kent S; Cromer D; Davenport M; Khoury D, 2022, Monoclonal antibody levels and protection from COVID-19, http://dx.doi.org/10.1101/2022.11.22.22282199

Cromer D; Steain M; Reynaldi A; Schlub T; Sasson S; Kent S; Khoury D; Davenport MP, 2022, Neutralising antibodies predict protection from severe COVID-19, http://dx.doi.org/10.1101/2022.06.09.22275942

Khoury D; Docken S; Subbarao K; Kent S; Davenport M; Cromer D, 2022, Predicting the efficacy of variant-modified COVID-19 vaccine boosters, http://dx.doi.org/10.1101/2022.08.25.22279237

Stadler E; Cromer D; Mehra S; Adekunle A; Flegg J; Anstey N; Watson J; Chu C; Mueller I; Robinson L; Schlub T; Davenport M; Khoury D, 2022, Risk of Plasmodium vivax recurrences follows a 30-70 rule and indicates relapse heterogeneity in the population, http://dx.doi.org/10.1101/2022.05.18.22275180

Khoury D; Steain M; Triccas J; Sigal A; Davenport M; Cromer D, 2021, A meta-analysis of Early Results to predict Vaccine efficacy against Omicron, http://dx.doi.org/10.1101/2021.12.13.21267748

Koutsakos M; Lee WS; Reynaldi A; Tan H-X; Gare G; Kinsella P; Liew KC; Williamson D; Kent H; Stadler E; Cromer D; Khoury D; Wheatley A; Juno J; Davenport M; Kent S, 2021, Dynamics of immune recall following SARS-CoV-2 vaccination or breakthrough infection, http://dx.doi.org/10.1101/2021.12.23.21268285

Aggarwal A; Stella AO; Walker G; Akerman A; Milogiannakis V; Brilot F; Amatayakul-Chantler S; Roth N; Coppola G; Schofield P; Jackson J; Henry J; Mazigi O; Langley D; Lu Y; Forster C; McAllery S; Mathivanan V; Fichter C; Hoppe AC; Munier ML; Jack H-M; Cromer D; Darley D; Matthews G; Christ D; Khoury D; Davenport M; Rawlinson W; Kelleher A; Turville S, 2021, SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern, http://dx.doi.org/10.1101/2021.12.14.21267772

Lee WS; Selva KJ; Davis S; Wines B; Reynaldi A; Esterbauer R; Kelly H; Haycroft E; Tan H-X; Juno J; Wheatley A; Hogarth M; Cromer D; Davenport M; Chung A; Kent S, 2020, Decay of Fc-dependent antibody functions after mild to moderate COVID-19, http://dx.doi.org/10.1101/2020.12.13.20248143

Price D; Shearer F; Meehan M; McBryde E; Moss R; Golding N; Conway E; Dawson P; Cromer D; Wood J; Abbott S; McVernon J; McCaw J, 2020, Early analysis of the Australian COVID-19 epidemic, http://dx.doi.org/10.1101/2020.04.25.20080127

Wheatley A; Juno J; Wang J; Selva K; Reynaldi A; Tan H-X; Shi Lee W; Wragg K; Kelly H; Esterbauer R; Davis S; Kent H; Mordant F; Schlub T; Gordon D; Khoury D; Subbarao K; Cromer D; Gordon T; Chung A; Davenport M; Kent S, 2020, Evolution of immunity to SARS-CoV-2, http://dx.doi.org/10.1101/2020.09.09.20191205

Cao P; Klonis N; Zaloumis S; Khoury DS; Cromer D; Davenport MP; Tilley L; Simpson JA; McCaw JM, 2017, A mechanistic model quantifies artemisinin-induced parasite growth retardation in blood-stage Plasmodium falciparum infection, http://dx.doi.org/10.48550/arxiv.1701.05302

Back to profile page